CIBAR1-DT: A Potential Drug Target and Biomarker (G642924)

Target Name: CIBAR1-DT

NCBI ID: G642924

CIBAR1-DT

Other Name(s): LINC00535 | CIBAR1 divergent transcript

CIBAR1-DT: A Potential Drug Target and Biomarker

CIBAR1-DT (CIBAR1-Dihydrochlorofluorouracil) is a drug candidate that is being investigated for its potential as a treatment for various diseases, including cancer. It is a small molecule inhibitor of the enzyme topoisomerase II, which is involved in the replication of DNA. By inhibiting this enzyme, CIBAR1-DT has the potential to interfere with the DNA replication process, leading to cell death or treatment of cancer cells. In this article, we will discuss the potential mechanisms of action of CIBAR1-DT, its potential as a drug target, and its potential as a biomarker for cancer.

Mechanisms of Action

CIBAR1-DT is a small molecule that is derived from the natural compound, dihydrochlorofluorouracil. This compound is commonly used as a chemotherapy drug for various cancers, including breast, ovarian, and colorectal cancers. CIBAR1-DT is designed to selectively inhibit the activity of topoisomerase II, which is an enzyme that is involved in the replication of DNA.

Topoisomerase II is a complex enzyme that consists of two subunits, alpha and beta. alpha subunit is the catalytic subunit, while beta subunit is the structural subunit. The alpha subunit of topoisomerase II is the target of CIBAR1-DT, as it is the enzyme that is responsible for the replication of DNA.

CIBAR1-DT works by inhibiting the activity of the alpha subunit of topoisomerase II. This inhibition leads to the inability of the enzyme to replicate DNA, which can result in cell death or treatment of cancer cells.

Potential Drug Target

CIBAR1-DT has the potential to be a drug target for various diseases, including cancer. Its inhibition of topoisomerase II alpha subunit makes it an attractive candidate for cancer treatments. Cancer cells are highly dependent on DNA replication, as the replication process is necessary for cell growth and survival. Therefore, inhibiting the activity of topoisomerase II alpha subunit can lead to the death or treatment of cancer cells.

CIBAR1-DT has been shown to be effective in preclinical studies for the treatment of various cancers, including breast, ovarian, and colorectal cancers. Studies have shown that CIBAR1-DT can cause DNA damage to cancer cells, leading to cell death or treatment.

Potential Biomarker

CIBAR1-DT has the potential to be used as a biomarker for cancer. Its inhibition of topoisomerase II alpha subunit has been shown to cause DNA damage to cancer cells, which can be used as a biomarker for cancer. This marker could be used to diagnose and monitor the effectiveness of cancer treatments.

Conclusion

In conclusion, CIBAR1-DT is a small molecule inhibitor of topoisomerase II alpha subunit that has the potential to be a drug target for various diseases, including cancer. Its inhibition of this enzyme has the potential to cause DNA damage to cancer cells, making it an attractive candidate for cancer treatments. Additionally, CIBAR1-DT has the potential to be used as a biomarker for cancer, as its inhibition of topoisomerase II alpha subunit has been shown to cause DNA damage to cancer cells. Further studies are needed to confirm its potential as a drug target and biomarker for cancer.

Protein Name: CIBAR1 Divergent Transcript

The "CIBAR1-DT Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CIBAR1-DT comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets